Warning: array_slice() expects parameter 1 to be array, boolean given in /home/pcgadvis/public_html/wp-content/themes/proactive/single-post_client.php on line 11

Warning: array_shift() expects parameter 1 to be array, null given in /home/pcgadvis/public_html/wp-content/themes/proactive/single-post_client.php on line 11

Company Overview: Cellectar Biosciences, Inc.

About the Company

Cellectar Biosciences, Inc.
Linkedin

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC Delivery Platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.


Investor Toolkit

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address